D2根治术后辅助化疗与Ⅱ、Ⅲ期胃癌患者预后的关系  

Relationship between Adjuvant Chemotherapy and Prognosis of Stage Ⅱ or Ⅲ Gastric Cancer Patients after D2 Radical Gastrectomy

作　　者：沈华[1] 殷先利[1] 刘振洋[1] 李勇[1] 曾毅栋[1] 曾德余[1] 杨晓琳[1] 向芳[1] 周慧俊[1] 李蓉蓉[1] 江少峰[1] 刘武[1] 

机构地区：[1]中南大学湘雅医学院附属肿瘤医院消化泌尿内科,湖南长沙410013

出　　处：《肿瘤药学》2015年第3期218-221,共4页Anti-Tumor Pharmacy

摘　　要：目的探讨Ⅱ、Ⅲ期胃癌患者D2根治术后辅助化疗与Ⅱ、Ⅲ期胃癌患者预后的关系。方法将326例行D2根治术的Ⅱ、Ⅲ期胃癌患者按照根治术后是否接受术后辅助化疗、化疗周期数以及化疗方案进行分组,比较各组的5年生存率有无差异。结果全组患者的5年总生存率为52%,化疗组和未化疗组的5年总生存率分别为58%和48%(χ2=2.876,P=0.090);化疗0周期(组一)、1-3周期(组二)、4周期及以上(组三)的5年生存率依次为48%、49%、68%,整体比较差异无统计学意义(χ2=5.957,P=0.051),仅组一与组三比较差异有统计学意义(χ2=5.908,P=0.015)。辅助化疗患者使用m DCF、FOLFOX和其它方案,3组的5年生存率依次为50%、60%、61%(χ2=0.290,P=0.865)。结论Ⅱ、Ⅲ期胃癌患者在D2根治术后给予不少于4周期的辅助化疗能提高其总生存率,但m DCF、FOLFOX和其它化疗方案之间未见明显差异。Objective To explore the relationship of adjuvant chemotherapy with the prognosis of gastric cancer patients in stageⅡ or Ⅲ after D2 radical gastrectomy. Methods The selected 326 cases of gastric cancer patients in stageⅡ or Ⅲ after D2 radical gastrectomy were grouped according to their own willingness of chemotherapy, different chemotherapy cycles and regimens. Compare the differences in 5-year survival rate between these groups. Results The 5-year survival rate was 52% for the whole patients. It was 58% and 48% respectively in the chemotherapy group and non-chemotherapy group（χ2=2.876, P=0.090）. In the 0 cycle chemotherapy group（group 1）, 1-3 cycles group（group 2）, and 4 cycles and above group（group 3）, the 5-year survival rate was respectively 48%, 49% and 68%. As a whole, there was no statistical differences（χ2=5.957, P=0.051）, but the difference between the group 1 and group 3 was statistically significant（χ2=5.908, P=0.015）. Adjuvant chemotherapy patients with m DCF, FOLFOX and other solutions had a 5-year survival rate of 50%, 60% and 61% respectively（χ2=0.290, P=0.865）. Conclusion Gastric cancer patients in stageⅡ or Ⅲcould have their overall survival improved by getting no less than 4 cycles of adjuvant chemotherapy after D2 radical gastrectomy. But m DCF, FOLFOX and other chemotherapy regimens made no obvious difference in improving overall survival.

关 键 词：胃癌 D2根治术 辅助化疗 预后 

分 类 号：R735.2[医药卫生—肿瘤]